| Oregon Health & Science University Patent applications |
| Patent application number | Title | Published |
|---|
| 20120116187 | METHOD AND APPARATUS FOR ASSESSMENT OF SLEEP DISORDERS - Embodiments provide systems, methods and apparatuses for monitoring the sleep of a subject in a home environment. In embodiments, load cells placed under bed supports may be coupled to a computing device that may process the load cell data to detect disordered breathing. In some embodiments, a computing device may apply a pattern recognition algorithm to load cell data to distinguish between normal movements and movements associated with a sleep disorder. In an embodiment, apparatuses and methods for monitoring sleep may perform functions associated with detection of sleep disturbances and/or identify a sleep disorder. | 05-10-2012 |
| 20120115904 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - Compounds of formula I: | 05-10-2012 |
| 20120114936 | THIN LAYER SUBSTRATE COATING AND METHOD OF FORMING SAME - Embodiments of the present invention relate to coating deposition and coatings for dental and orthopedic devices that provide prevention or reduction of ion leakage and, in some situations, improved aesthetic appearances. | 05-10-2012 |
| 20120088255 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 10 | 04-12-2012 |
| 20120063665 | METHOD AND APPARATUS FOR QUANTITATIVE IMAGING OF BLOOD PERFUSION IN LIVING TISSUE - Embodiments provide methods and systems for imaging, and, more specifically, to a method and apparatus for quantitative imaging of blood perfusion in living tissue. Some embodiments are directed to methods of obtaining quantitative imaging of blood perfusion in living tissues using Doppler optical micro-angiography (DOMAG). | 03-15-2012 |
| 20120045755 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 10 | 02-23-2012 |
| 20120014881 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 01-19-2012 |
| 20120010237 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - A method for inhibiting a parasitic or infectious disease in a subject, wherein the parasitic or infectious disease is selected from one caused by | 01-12-2012 |
| 20110313262 | METHOD AND APPARATUS FOR PREVENTION OF APNEA - Embodiments provide a continuous monitor of a patient's oxygenation and/or respiration coupled to a device configured to stimulate the patient's respiratory drive and/or summon medical assistance. In embodiments, there are provided systems, devices, and methods to assist in preventing patients from overdosing themselves with narcotics post-surgery. In embodiments, an apnea prevention device (APD) may utilize a commercially available pulse oximeter and/or a respiratory monitor to continuously monitor a patient's level of oxygenation/respiration. Should a patient develop respiratory depression or apnea and begin to desaturate, an APD may, using a proprietary method, trigger a sequence of staged responses to reverse worsening hypoxia. | 12-22-2011 |
| 20110262479 | RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells. | 10-27-2011 |
| 20110228907 | HEAD AND NECK RADIATION LOCALIZATION USING ORAL APPLIANCE - In various embodiments, methods, apparatuses, and systems for accurate patient positioning and motion tracking before and/or during head and neck radiation therapy, such as intensity modulated radiation therapy, are provided. In exemplary embodiments, a computing system may be endowed with one or more components of the disclosed apparatuses and/or systems and may be employed to perform one or more methods as disclosed herein. Exemplary embodiments provide head and neck radiation localization using, in part, an oral appliance. | 09-22-2011 |
| 20110201917 | METHOD AND APPARATUS USING MAGNETIC RESONANCE IMAGING FOR CANCER IDENTIFICATION - Embodiments provide a Magnetic Resonance Imaging (MRI) technique and optionally software—collectively referred to as the “shutter-speed” model—to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination, effectively eliminating or limiting the false positives suffered by existing MRI techniques. | 08-18-2011 |
| 20110195064 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients. | 08-11-2011 |
| 20110194075 | METHOD AND APPARATUS FOR VISUAL FIELD MONITORING - Embodiments provide methods and systems for the modeling and analysis of visual fields. Methods for global and regional measurement of visual sensitivity and quantification of field loss are provided in accordance with various embodiments. Further embodiments provide systems and methods for the diagnosis of diseases affecting the visual field. In addition, embodiments provide methods and systems for measuring and quantifying the volume of the Hill of Vision for an individual subject. | 08-11-2011 |
| 20110116694 | RAPID CONFOCAL MICROSCOPY TO SUPPORT SURGICAL PROCEDURES - One embodiment of techniques for confocal microscopy includes illuminating a spot on a surface of a biological sample. A first emission intensity from the spot is detected in a first range of optical properties; and a second emission intensity in a second range. A pixel that corresponds to the spot is colored using a linear combination of the first and second emission intensities. Sometimes, the pixel is colored to approximate a color produced by histology. In some embodiments, a surface of a sample is contacted with a solution of acridine orange. Then, a spot is illuminated with a laser beam of wavelength about 488 nanometers (nm). Fluorescence emission intensity is detected above about 500 nm. Sometimes, a certain illumination correction is applied. In some embodiments, a sample holder that compresses a sample is removable from a stage that is fixed with respect to a focal plane of the microscope. | 05-19-2011 |
| 20110092860 | SYSTEM FOR CLINICAL ASSESSMENT OF MOVEMENT DISORDERS - According to one embodiment of the present invention, the system for clinical assessment of movement disorders (iTUG) is comprised of a) a protocol to assess gait, balance, and mobility; b) a plurality of wearable sensors including accelerometers, gyroscopes, magnetometers, optical sensors, and goniometers to record kinematics data obtained from a patient during said protocol; c) means for wirelessly transmitting said kinematics data to a storage and data processing server; and d) a plurality of statistical and biomedical signal processing methods to analyze said kinematic data and derive a plurality of metrics (outcomes) to objectively quantify movement disorders. A specially important outcome for the assessment of movement disorders is described, namely, the quantification of the onset and offset parameters during turning. A method for quantification of said onset and offset turning parameters involves 1) collecting data to measure the angle of the trunk during turning, 2) modeling said angle using a mathematical model, and 3) using numerical optimization and estimation methods for fitting the model in the data to determine said onset and offset turning parameters. | 04-21-2011 |
| 20110081730 | ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 04-07-2011 |
| 20110053830 | METHODS FOR TREATING SEPTIC SHOCK - Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a peptide is administered to a subject with septic shock, such as septic shock induced by an infection with gram negative bacteria. | 03-03-2011 |
| 20110046482 | METHODS FOR REDUCING TOXICITIES ASSOCIATED WITH MEDICAL PROCEDURES EMPLOYING RADIOGRAPHIC CONTRAST AGENTS - Improved methods of administration of thiol-based agents, such as NAC (N-acetylcysteine) and STS (sodium thiosulfate), are provided that protect against renal and other organ injury caused by diagnostic or therapeutic intra-arterial procedures which employ radiographic contrast agents. | 02-24-2011 |
| 20110014224 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 01-20-2011 |
| 20110004099 | METHOD AND APPARATUS USING ULTRASOUND FOR ASSESSING INTRACARDIAC PRESSURE - Embodiments relate to the field of hemodynamics, and, more specifically, to non-invasive methods of intracardiac pressure assessment. Some embodiments include acquiring ultrasound image data of a right internal jugular (IJ) vein in a subject, processing the ultrasound image data to determine vascular characteristic data for the IJ vein, and determining the right-sided intracardiac pressure from the vascular characteristic data. Also disclosed are systems and apparatus for carrying out the methods. | 01-06-2011 |
| 20100316653 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ORTHOPOXVIRUSES - In particular aspects, the invention provides a novel approach for the systematic analysis and identification of biologically relevant epitopes (SABRE). SABRE-identified polypeptides have diagnostic (e.g., polypeptide arrays, etc.) and/or therapeutic (e.g., vaccines, etc.) utility, and utility for developing monoclonal antibodies having diagnostic and/or therapeutic utility (e.g. for detecting and/or preventing orthopoxvirus infection). Preferred aspects provide high-throughput assays for detecting specific orthopoxvirus infection, for detecting orthopoxvirus-specific immune response, or for dual (parallel) determination of both orthopoxvirus immune response and orthopoxvirus infection. Additional preferred and surprising aspects provide novel high-throughput methods for detecting ‘protective immunity’ against orthopoxviruses (e.g., for detecting protective immunity against smallpox virus and monkeypox virus), based on anti-vaccinia virus serum antibody levels. The inventive diagnostic assays are rapid, high-throughput and suitable for ‘point-of-care’ implementations. | 12-16-2010 |
| 20100268230 | METHOD AND APPARATUS FOR DENS FRACTURE FIXATION - Embodiments of the present invention provide methods, apparatuses, and systems for fixing dens fractures. The mode of failure for screw fixation of C2 dens fractures is often via cut-out at the anterior body. In an embodiment, securing a plate, such as a locking plate, to the anterior surface of the vertebra attached directly to an interfragmentary screw may reduce potential for anterior screw cut-out and improve construct strength. Plate supplementation of anterior screw fixation of Type II dens fractures thus improves construct strength and changes the failure mechanism from anterior screw cut-out to posterior displacement of the screw, thus improving clinical outcomes for these fractures. | 10-21-2010 |
| 20100268188 | DRUG DELIVERY CUFF - Embodiments provide a drug delivery cuff including a drug reservoir. In an embodiment, an integrated drug pump may be provided. A drug delivery cuff in accordance with an embodiment may be placed around any suitable vascular graft (e.g., ePTFE) or directly around any natural tissue conduit (e.g., perivascularly), at any position along the graft/conduit or overlapping a graft and conduit, either at the time of graft surgical placement or separate therefrom. | 10-21-2010 |
| 20100267027 | HER-2 BINDING ANTAGONISTS - There is disclosed a a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 10 | 10-21-2010 |
| 20100233211 | ATTENUATED FRANCISELLA AND METHODS OF USE - is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuated | 09-16-2010 |
| 20100222712 | BIAS-PROBE ROTATION TEST OF VESTIBULAR FUNCTION - Apparatus and methods for rotation test stimulus and analysis methods overcome many of the limitations of traditional clinical tests of peripheral vestibular function. An embodiment includes a rotational stimuli applied to the rotational motion for testing that includes two separate components, a bias component and a probe component. The bias component for rotational motion is designed to temporarily turn off vestibular responses in one ear while the responsiveness in the opposite ear is simultaneously evaluated using the probe component of the stimulus. Responses from application of these stimuli are analyzed by isolating and separating the bias response from the probe response. The bias and probe component responses are parameterized by applying curve fits of mathematical functions to the isolated bias and probe component responses. These parameters characterize the patient's vestibular function. | 09-02-2010 |
| 20100129923 | TANDEM MASS SPECTROMETRY FOR DETECTING AND/OR SCREENING FOR CONDITIONS ASSOCIATED WITH ALTERED STEROLS - Embodiments of the present invention provide for detecting and/or screening for conditions associated with altered sterols by dehvatization of sterols to provide suitable sensitivity and selectivity of detection using tandem mass spectrometry with electrospray ionization. Such testing may be performed to detect and/or screen for conditions such as Smith-Lemli-Opitz syndrome, familial hypercholesterolemia, and cerebrotendinous xanthomatosis, or certain bile acid disorders. | 05-27-2010 |
| 20100129292 | METHOD AND APPARATUS FOR NONINVASIVE QUANTITATIVE DETECTION OF FIBROSIS IN THE HEART - Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein. | 05-27-2010 |
| 20100125950 | ACCESSORY PANEL FOR DIAGNOSTIC PLATFORM, PATIENT BED AND OTHER SUPPORT SURFACES - Embodiments herein provide a flexible accessory panel with apertures from which items may be suspended. In particular, receptacles for fluids draining from a patient may be suspended from the apertures, which are retained at a level below that of the patient, maintaining a gravitational flow. Maintaining downward flow of the draining fluids limits the backflow of draining fluid to the patient and reduces the risk of infection. | 05-27-2010 |
| 20100120143 | INDUCTION OF APOPTOSIS AND CELL GROWTH INHIBITION BY PROTEIN 4.33 - There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specific cell-surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. In particular aspects, IGFBP-3 and P4.33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4.33 is an important mediator of IGF-independent growth inhibitory actions of IGFBP-3. The P4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression. | 05-13-2010 |
| 20100119521 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY MODULATING HER-2 AND EGF RECEPTORS - An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor. Herstatin blocked the activated Akt-mediated EGF survival signal, as well as transforming growth factor alpha (TGFα)-mediated EGF receptor activation, survival signal and proliferation signal. Purified recombinant herstatin specifically inhibited human carcinoma cells that over-express HER-2, and was effectively absorbed into the blood of intraperitoneally injected mice, where it was not proteolytically degraded and was present for between one and three hours. | 05-13-2010 |
| 20100016755 | METHOD AND APPARATUS FOR TINNITUS EVALUATION - Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test. | 01-21-2010 |
| 20090281466 | DEVICE FOR REHABILITATION OF INDIVIDUALS EXPERIENCING LOSS OF SKELETAL JOINT MOTOR CONTROL - A method and device assist in the rehabilitation of patients who have suffered loss of motor control of an appendicular joint due to neurological damage. The method includes attempted contraction by a patient of a muscle that serves to move an affected joint coupled with the production of a perception by the patient that the joint is being moved more than it really is. The method results in dramatic non-transient improvements in motor control of the joint. The device provides an apparatus for performance of the method. | 11-12-2009 |
| 20090270316 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. | 10-29-2009 |
| 20090253152 | NOVEL MUTANT IGFBP-3 MOLECULES THAT DO NOT BIND TO IGFs, BUT RETAIN THEIR ABILITY TO FUNCTIONALLY BIND IGFBP-3 RECEPTOR - There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4.33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional exemplary embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor. | 10-08-2009 |
| 20090124698 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE - The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions. | 05-14-2009 |
| 20090105347 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF - Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed | 04-23-2009 |
| 20080319425 | DRUG-ELUTING GRAFT - Embodiments of the present invention provide a device for the local delivery of a substance into a natural tissue conduit in the mammalian body, having a first element capable of contacting the lumen of the conduit and a second element which overlays first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit such that a substance placed in the reservoir is delivered into the conduit. In embodiments, the first element may be fully or partially microporous or a separate intermediate microporous membrane may be provided. Also provided are methods of mixing or moving a drug within a reservoir using various mixing elements. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing a device in accordance with embodiments of the present invention. | 12-25-2008 |
| 20080286807 | Methods and Reagents for Elimination or Reduction of False Positives in the Analysis of a Sample - Methods, apparatuses, and systems for eliminating or reducing false positives in assays are provided. More specifically, there is provided a method to absorb a false positive signal with an absorber in favor of detecting a true positive signal. Embodiments of the present invention include but are not limited to systems and methods for detecting antibodies with greater specificity than available assays and also for detecting a greater variety of antibodies. | 11-20-2008 |
| 20080286209 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure - Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.). Particular pharmaceutical compositions and methods comprise the use of at least one compound selected from the group consisting of: (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (all-trans farnesol); (2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (cis-farnesol); (E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol nerolidol); (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-amine (farnesylamine); (E)-3-(3,7-dimethylocta-2,6-dienyloxy)phenol (geranylresorcinol); (2E,6E)-,7,11-dimethyl-3-(trifluoromethyl)dodeca-2,6,10-trien-1-ol (trifluorofarnesol); and (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraen-1-ol (all-trans retinol). According to additional aspects, compounds that target and inhibit enzymes that degrade/metabolize/inactivate the disclosed compounds have utility to induce endogenous accumulation thereof to suppress/prevent, e.g., alcohol withdrawal seizures or convulsive seizures. | 11-20-2008 |
| 20080269463 | Tropoelastin Isoforms and Used Thereof - This disclosure provides new isoforms of tropoelastin. The disclosure further provides methods for making and using these isoforms, alone or in combination with each other or other isomers, such as in the production of biomaterials. | 10-30-2008 |
| 20080227761 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 09-18-2008 |
